Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 ...

This stock is a great choice for cautious and aggressive investors.

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...

Wall Street saw record highs on Tuesday driven by a rally in AI-charged chip stocks and a price boost for Moderna. The Dow ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

Both vaccines work. But Pfizer requires a longer waiting period before the vaccine kicks in, while Moderna has stronger side effects.

Forbes contributors publish independent expert analyses and insights. Jack is a career business journalist an an award-winning podcast host. Speed-to-market has always been critical in the life ...

Moderna (NASDAQ: MRNA) provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million ...

Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 ...